Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases.

SB 9200: A Potential Breakthrough Drug for HCV

Latest News

    • 23 JUN 14
    • 0

    Spring Bank Pharmaceuticals Presents at the Nucleic Acid Summit 2014

    MILFORD, Mass. – June 23, 2014  Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced two presentations at the Nucleic Acid Summit 2014 held June 19-20, 2014 in San Diego. “The research presented continues

    Read more →

Publications

  • Coughlin, J. E., Pandey R. K., Padmanabhan, S. O’Loughlin, K.,Green,C. E., Mirsalis,J., Iyer, R. P. Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-HBV dinucleoside phosphorothioate. Drug Disposition and Metabolism (The American Society for Pharmacology and Experimental Therapeutics). 2012, 40, 970-981.
  • Ambre, P K., Pissurlenkar, R. R. S., Coutinho, E. C., Iyer, R. P. A unified model for Checkpoint-Kinase-1 inhibitors based on Docking, 3D-QSAR, and Pharmacophore modeling. Can. J. Chem. 2012, 90, 675–692.
  • Rhee, S-W., Iyer, R. P., Coughlin, J., Padmanabhan, S., Malerich, J. P., Tanga, M. J. Synthesis of a 35S-labeled dinucleoside phosphorothioate prodrug, an orally bioavailable anti-HBV agent. J. of Radiolabeled Compounds, 2012
  • Pissurlenkar, R.R.S., Khedkar, V. M., Iyer, R. P., Coutinho, E. Ensemble QSAR: A QSAR method based on conformational ensembles and metric descriptors. J. Comput. Chem. 2011, 32: 2204–2218.